Literature DB >> 7999033

Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation.

J Szebeni1, N M Wassef, H Spielberg, A S Rudolph, C R Alving.   

Abstract

Intravenous injection of hemoglobin-containing liposomes (LEH) caused a significant reduction in plasma hemolytic complement activity in rats on a time scale of minutes. Liposomes without hemoglobin also caused complement consumption, but less than LEH, while free hemoglobin was without effect. Consistent with complement activation, the LEH-induced drop in plasma hemolytic complement activity was closely paralleled by an increase in plasma thromboxane B2 level. Studies to determine the mechanism of complement activation demonstrated the presence of natural antibodies in rat serum against all lipid components of LEH, thus, the potential for classical pathway activation. Yet, in vitro incubation of LEH with rat serum showed that: 1) EGTA/Mg++, which inhibits complement activation through the classical pathway, did not inhibit complement consumption by LEH, and 2) the use of serum preheated at 50 degrees C, which inhibits C activation through the alternative pathway by selectively depleting factor B, effectively reversed the complement-consuming effect of LEH. Consequently, LEH-induced complement activation in rat serum seems to involve primarily the alternative pathway.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7999033     DOI: 10.1006/bbrc.1994.2658

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

2.  Biological evaluation of liposome-encapsulated hemoglobin surface-modified with a novel PEGylated nonphospholipid amphiphile.

Authors:  Vivek R Yadav; Okhil Nag; Vibhudutta Awasthi
Journal:  Artif Organs       Date:  2014-04-22       Impact factor: 3.094

3.  Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover.

Authors:  Islam Hamad; A Christy Hunter; Kenneth J Rutt; Zhuang Liu; Hongjie Dai; S Moein Moghimi
Journal:  Mol Immunol       Date:  2008-07-03       Impact factor: 4.407

Review 4.  Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management.

Authors:  J Szebeni; S Fishbane; M Hedenus; S Howaldt; F Locatelli; S Patni; D Rampton; G Weiss; J Folkersen
Journal:  Br J Pharmacol       Date:  2015-10-25       Impact factor: 8.739

5.  Complement Activation-Related Pathophysiological Changes in Anesthetized Rats: Activator-Dependent Variations of Symptoms and Mediators of Pseudoallergy.

Authors:  László Dézsi; Tamás Mészáros; Erik Őrfi; Tamás G Fülöp; Mark Hennies; László Rosivall; Péter Hamar; János Szebeni; Gábor Szénási
Journal:  Molecules       Date:  2019-09-09       Impact factor: 4.411

6.  PEGylated Liposomal Methyl Prednisolone Succinate does not Induce Infusion Reactions in Patients: A Correlation Between in Vitro Immunological and in Vivo Clinical Studies.

Authors:  Yaelle Bavli; Bing-Mae Chen; Steve R Roffler; Marina A Dobrovolskaia; Eldad Elnekave; Shifra Ash; Yechezkel Barenholz; Keren Turjeman
Journal:  Molecules       Date:  2020-01-28       Impact factor: 4.411

7.  Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm.

Authors:  Gergely Tibor Kozma; Tamás Mészáros; Tamás Bakos; Mark Hennies; Dániel Bencze; Barbara Uzonyi; Balázs Győrffy; Edward Cedrone; Marina A Dobrovolskaia; Mihály Józsi; János Szebeni
Journal:  Front Immunol       Date:  2021-04-28       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.